The role of regorafenib in metastatic colorectal cancer

Affiliations

¹ Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil.
² Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address: grothey.axel@mayo.edu.

Comment

Rachel Riechelmann et al. Lancet Oncol. 2015 Jun.

. 2015 Jun;16(6):596-7.

doi: 10.1016/S1470-2045(15)70191-9. Epub 2015 May 13.

¹ Instituto do Cancer do Estado de São Paulo, São Paulo, Brazil.
² Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA. Electronic address: grothey.axel@mayo.edu.

No abstract available

Comment on

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, Xu J, Bai Y, Chi Y, Wang L, Yeh KH, Bi F, Cheng Y, Le AT, Lin JK, Liu T, Ma D, Kappeler C, Kalmus J, Kim TW; CONCUR Investigators. Li J, et al. Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13. Lancet Oncol. 2015. PMID: 25981818 Clinical Trial.